2024-05-07 23:34:06 ET
Myriad Genetics, Inc. (MYGN)
Q1 2024 Earnings Conference Call
May 7, 2024 4:30 PM ET
Company Participants
Matthew Scalo - Senior Vice President of Investor Relations
Paul Diaz - President and Chief Executive Officer
Mark Verratti - Chief Commercial Officer
Sam Raha - Chief Operating Officer
Scott Leffler - Chief Financial Officer
Conference Call Participants
Matthew Sykes - Goldman Sachs
Doug Schenkel - Wolfe Research, LLC
Daniel Brennan - TD Cowen
Puneet Souda - Leerink Partners LLC
Andrew Cooper - Raymond James Financial, Inc.
Rachel Vatnsdal - JPMorgan Chase & Co.
Subbu Nambi - Guggenheim Securities, LLC
Jacob Krahenbuhl - Stephens Inc.
John Kim - Bank of America
Presentation
Operator
Thank you for standing by, and welcome to Myriad Genetics First Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question-and-answer session. [Operator Instructions]
I would now like to hand the call over to Matt Scalo. Please go ahead.
Matthew Scalo
Thanks, Latif, and good afternoon and welcome to the Myriad Genetics first quarter 2024 earnings call. During the call, we will review the financial results we released today and afterwards we will host a question-and-answer session. Our quarterly earnings release was issued this afternoon on Form 8-K and can be found on our website at investor.myriad.com.
I’m Matt Scalo, Senior Vice President of Investor Relations, and on the call with me today are Paul Diaz, President and Chief Executive Officer; Scott Leffler, our Chief Financial Officer; Sam Raha, our Chief Operating Officer; and Mark Verratti, our Chief Commercial Officer. This call can be heard live via webcast at investor.myriad.com, and a recording will be archived in the Investors section of our website along with this slide presentation.
Please note that some of the information presented today contains projections or other forward-looking statements regarding future events or the future financial performance of the company. These statements are based on management’s current expectations, and the actual events or results may differ materially and adversely from these expectations for a variety of reasons. We refer you to the documents the company files from time to time at the Securities and Exchange Commission, specifically the company’s annual report on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual result to different materially from those contained in our projections or forward-looking statements.
I will now turn the call over to Paul.
Paul Diaz
Thanks, Matt. Good afternoon, everyone, and thank you for joining us. On today’s call, we will discuss highlights for our strong first quarter performance, provide an update of the progress that the team has made accelerating profitable revenue growth. First, I want to thank my Myriad teammates and our provider partners for their continued support and commitment to advancing our mission and vision to make genetic testing and precision medicine more accessible and helping people take more control of their health.
We’ll now turn to Slide 4 to talk about our highlights for the quarter. We continue to deliver on our commitment to shareholders as we achieved double-digit revenue growth in the first quarter compared to last year. Talking both volume growth and ASP improvements across the portfolio. Our focus on profitable growth continues into 2024 as we reported positive adjusted EBITDA when we’re close to breakeven on an adjusted EPS basis in the first quarter....
Read the full article on Seeking Alpha
For further details see:
Myriad Genetics, Inc. (MYGN) Q1 2024 Earnings Call Transcript